<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405821</url>
  </required_header>
  <id_info>
    <org_study_id>999907032</org_study_id>
    <secondary_id>07-I-N032</secondary_id>
    <nct_id>NCT00405821</nct_id>
  </id_info>
  <brief_title>Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir Prophylaxis Versus Placebo Among HIV-1/HSV-2 Co-Infected Individuals in Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Genomics Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether acyclovir, a medicine used to treat herpes simplex virus 2
      (HSV-2), can slow down the progression (worsening) of HIV disease in people with both HIV and
      HSV-2 infections. HSV-2 increases the amount of HIV virus in the blood of infected people and
      may make HIV progress faster. The study will evaluate:

      &quot;Whether people who take acyclovir can avoid antiretroviral treatment until later in their
      lives

      &quot;Whether people who take acyclovir get fewer genital ulcers

      &quot;How well people are able to take acyclovir and any side effects they experience from it

      &quot;Differences in the amount of HIV virus in the blood of patients who are and are not taking
      acyclovir, and how HIV/AIDS is different in these patients.

      People 18 years of age and older living in the Rakai district of Uganda who are infected with
      both HIV (early stage disease) and HSV-2 may be eligible for this study. Participants are
      randomly assigned to take the study drug, acyclovir, or a placebo (look-alike pill with no
      active ingredient) daily for 2 years. During this time, they visit the clinic once a month
      for a routine physical examination. Patients who develop genital ulcers or complications of
      HIV are treated for the problem, and patients whose HIV disease progresses, requiring them to
      begin antiretroviral therapy, are treated accordingly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventions that slow HIV-1 disease progression among persons with CD4+ counts above 250
      cells/microliter could postpone the need for antiretroviral therapy (ART) and prolong
      life-expectancy for HIV-infected persons. Herpes simplex virus type 2 (HSV-2) has been shown
      to up-regulate HIV-1 replication at the cellular level. (1) This finding has been supported
      by clinical evidence that individuals who are HSV-2 seropositive at the time of HIV-1
      seroconversion had higher HIV viral loads at 5 and 15 months post-seroconversion. (2) Earlier
      studies during the era of zidovudine (Retrovir) monotherapy showed a survival advantage when
      acyclovir (ACV, Zovirax) was added to the treatment of patients with HIV. (3) Acyclovir
      prophylaxis has been shown to decrease herpes simplex virus infections and varicella-zoster
      virus infections among HIV infected patients in a meta-analysis of randomized trials from
      North America and Europe. This analysis also found a reduced risk of mortality among patients
      treated with acyclovir. The potential of acyclovir to slow HIV-1 disease progression has not
      been assessed in a randomized trial in Africa where high rates of HSV-2 infection have been
      observed among HIV-1 infected individuals. This study proposes to assess the benefits of
      acyclovir prophylaxis among HIV-1 infected individuals dually infected with HSV-2 who are not
      on ART through a randomized double-blind placebo controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the effect of acyclovir prophylaxis vs placebo among HIV-1/HSV-2 co-infected individuals on the progression to AIDS (CD4+ less than 250 cells/microliter or World Health Org stage IV disease, excluding esophageal candidiasis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Number of Episodes of Genital Ulcer Disease Between Arms</measure>
    <time_frame>2 years</time_frame>
    <description>We calculated incidence rate for each treatment arm for episodes of genital ulcer disease, and incidence rate ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 Viral Load Difference Between Arms</measure>
    <time_frame>baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
    <description>We measured mean annual rate of change in log10 viral load (copies/mL) for each group. We assessed difference in annual rate of change in log10 viral load (copies/mL) between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of Acyclovir</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Acyclovir</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic and Immunologic Responses to ART in Those Who Progress to CD+4 Less Than 250cells/mL</measure>
    <time_frame>6 months and 12 moths post ART initiation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>HIV Infections</condition>
  <condition>Herpes Genitalis</condition>
  <arm_group>
    <arm_group_label>Acyclovir 400mg tablet twice daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet twice daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
    <description>400mg twice daily for 24 months</description>
    <arm_group_label>Acyclovir 400mg tablet twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice daily for 24 months</description>
    <arm_group_label>Placebo tablet twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Documentation of HIV-1 infection, by either two positive ELISAs or two discrepant
                  ELISAs with a confirmatory positive Western Blot

               2. Documentation of prior HSV-2 infection by Focus Kalon ELISA

               3. Absolute CD4+ T-cell count of greater than or equal to 300 and less than or equal
                  to 400 cells/microliter within 30 days prior to randomization

               4. All participants must be receiving Cotrimoxazole prophylaxis as part of standard
                  care unless contraindicated

               5. Age at least 18 years and above

               6. Laboratory values (within 30 days prior to randomization)

                    1. Aspartate transaminase (AST) no more than five times the upper limit of
                       normal (ULN)

                    2. Total bilirubin no more than 2 times ULN

                    3. Creatinine no more than 2.0 mg/dL

                    4. Platelet count at least 50 000/microliter

                    5. Hemoglobin at least 8g/dL

               7. Written informed consent

        EXCLUSION CRITERIA:

          1. Concurrent malignancy or any other disease state requiring cytotoxic chemotherapy

          2. Symptomatic for significant HIV-related illnesses (WHO stage III or IV), such as
             opportunistic infections and malignancies other than mucocutaneous Kaposi's sarcoma. A
             history of AIDS defining opportunistic infections other than mucocutaneous Kaposi's
             sarcoma or candida or treated tuberculosis

          3. Active HSV-2 disease as suggested by painful genital ulcer disease at time of
             screening or enrollment

          4. Current use of antiretroviral medications or Preventing Mother-to-Child Transmission
             (PMTCT) use of antiretrovirals within the previous 6 months

          5. Significant cardiac, pulmonary, kidney, rheumatologic, gastrointestinal, or CNS
             disease as detectable on routine medical history, physical examination, or screening
             laboratory studies.

          6. Psychiatric illness that, in the opinion of the PI, might interfere with the study
             compliance.

          7. Active substance abuse or history of prior substance abuse that may interfere with
             protocol compliance or patient safety.

          8. CD4+ count less than 300 or more than 400 cells/microliter.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Reynolds, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rakai Health Sciences Program, Uganda Virus Research Institute</name>
      <address>
        <city>Kalisizo</city>
        <state>Rakai District</state>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Moriuchi M, Moriuchi H, Williams R, Straus SE. Herpes simplex virus infection induces replication of human immunodeficiency virus type 1. Virology. 2000 Dec 20;278(2):534-40.</citation>
    <PMID>11118375</PMID>
  </reference>
  <reference>
    <citation>Serwadda D, Gray RH, Sewankambo NK, Wabwire-Mangen F, Chen MZ, Quinn TC, Lutalo T, Kiwanuka N, Kigozi G, Nalugoda F, Meehan MP, Ashley Morrow R, Wawer MJ. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis. 2003 Nov 15;188(10):1492-7. Epub 2003 Oct 28.</citation>
    <PMID>14624374</PMID>
  </reference>
  <reference>
    <citation>Stein DS, Graham NM, Park LP, Hoover DR, Phair JP, Detels R, Ho M, Saah AJ. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med. 1994 Jul 15;121(2):100-8.</citation>
    <PMID>8017721</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <results_first_submitted>July 18, 2012</results_first_submitted>
  <results_first_submitted_qc>August 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2012</results_first_posted>
  <last_update_submitted>August 28, 2012</last_update_submitted>
  <last_update_submitted_qc>August 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Steven Reynolds</investigator_full_name>
    <investigator_title>Scientific Director NIH-Uganda ICER</investigator_title>
  </responsible_party>
  <keyword>AIDS</keyword>
  <keyword>HIV Disease Progression</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>HIV Viral Load</keyword>
  <keyword>Genital Ulcers</keyword>
  <keyword>HIV</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>440 HIV+ subjects recruited in rural Rakai, Uganda within the Rakai Health Sciences Program mobile medical clinic during May 2007 thru November 2008</recruitment_details>
      <pre_assignment_details>All subjects were randomized to study arm, and initiated study treatment at the time of enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acyclovir 400mg Tablet Twice Daily</title>
        </group>
        <group group_id="P2">
          <title>Placebo Tablet Twice Daily</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>initiated ART</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acyclovir 400mg Tablet Twice Daily</title>
        </group>
        <group group_id="B2">
          <title>Placebo Tablet Twice Daily</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="220"/>
            <count group_id="B2" value="220"/>
            <count group_id="B3" value="440"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50+ years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis)</title>
        <description>Evaluate the effect of acyclovir prophylaxis vs placebo among HIV-1/HSV-2 co-infected individuals on the progression to AIDS (CD4+ less than 250 cells/microliter or World Health Org stage IV disease, excluding esophageal candidiasis)</description>
        <time_frame>2 years</time_frame>
        <population>Intention to treat analysis of all subjects randomized on the trial meeting the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir 400mg Tablet Twice Daily</title>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet Twice Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis)</title>
          <description>Evaluate the effect of acyclovir prophylaxis vs placebo among HIV-1/HSV-2 co-infected individuals on the progression to AIDS (CD4+ less than 250 cells/microliter or World Health Org stage IV disease, excluding esophageal candidiasis)</description>
          <population>Intention to treat analysis of all subjects randomized on the trial meeting the primary endpoint</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intent-to-treat analysis used Cox proportional hazards (CPH) models, adjusting for baseline log10 viral load (VL), CD4 cell count, gender and age to assess the risk of disease progression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P-value was adjusted to include multiple looks at data including an interim efficacy review at 50% and 75% accrual of person-years on study</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>adjusted for baseline log10 viral load, baseline CD4 count, gender, and age</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Number of Episodes of Genital Ulcer Disease Between Arms</title>
        <description>We calculated incidence rate for each treatment arm for episodes of genital ulcer disease, and incidence rate ratio.</description>
        <time_frame>2 years</time_frame>
        <population>We conducted monthly clinical assessment for GUD on all randomized subjects during their entire follow-up period on this trial. The number of episodes of GUD is shown below.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir 400mg Tablet Twice Daily</title>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet Twice Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Difference in Number of Episodes of Genital Ulcer Disease Between Arms</title>
          <description>We calculated incidence rate for each treatment arm for episodes of genital ulcer disease, and incidence rate ratio.</description>
          <population>We conducted monthly clinical assessment for GUD on all randomized subjects during their entire follow-up period on this trial. The number of episodes of GUD is shown below.</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference by treatment arm in rate of GUD.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>we included multiple GUD events per subject in the estimate of GUD incidence</p_value_desc>
            <method>rate ratio with 95% CI</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 Viral Load Difference Between Arms</title>
        <description>We measured mean annual rate of change in log10 viral load (copies/mL) for each group. We assessed difference in annual rate of change in log10 viral load (copies/mL) between groups.</description>
        <time_frame>baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
        <population>We measured viral load at baseline and at 6 monthly follow-up visits during 24 months of follow-up for all subjects randomized on this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir 400mg Tablet Twice Daily</title>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet Twice Daily</title>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Viral Load Difference Between Arms</title>
          <description>We measured mean annual rate of change in log10 viral load (copies/mL) for each group. We assessed difference in annual rate of change in log10 viral load (copies/mL) between groups.</description>
          <population>We measured viral load at baseline and at 6 monthly follow-up visits during 24 months of follow-up for all subjects randomized on this study.</population>
          <units>log10 (copies/mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.061" lower_limit="-0.250" upper_limit="0.129"/>
                    <measurement group_id="O2" value="0.402" lower_limit="0.212" upper_limit="0.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference in annual rate of change in log10 viral load by arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.463</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.731</ci_lower_limit>
            <ci_upper_limit>-0.194</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity of Acyclovir</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Acyclovir</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic and Immunologic Responses to ART in Those Who Progress to CD+4 Less Than 250cells/mL</title>
        <time_frame>6 months and 12 moths post ART initiation</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>maximum follow-up time on this study ranged from 24 months to 41 months depending on time of enrollment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acyclovir 400mg Tablet Twice Daily</title>
        </group>
        <group group_id="E2">
          <title>Placebo Tablet Twice Daily</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peptic ulcer disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Abdominal pain, unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Febrile Illness, unspecified</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>TB Adenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="220"/>
                <counts group_id="E2" events="34" subjects_affected="24" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>skin infection, unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>EENT infection, unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Bacterial pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="220"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Extra-pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cryptococcal meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Esophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Genito-urinary disease (GUD)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma to chest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="220"/>
                <counts group_id="E2" events="52" subjects_affected="41" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pregnancy complication, unspecified</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory complaint, unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>wound, unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="218" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="41" subjects_affected="32" subjects_at_risk="220"/>
                <counts group_id="E2" events="58" subjects_affected="41" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Loss</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="220"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic conjunctivitis</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="220"/>
                <counts group_id="E2" events="29" subjects_affected="21" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peptic ulcer disease</sub_title>
                <counts group_id="E1" events="124" subjects_affected="63" subjects_at_risk="220"/>
                <counts group_id="E2" events="115" subjects_affected="60" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="220"/>
                <counts group_id="E2" events="42" subjects_affected="33" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastrointestinal, other complaint</sub_title>
                <counts group_id="E1" events="415" subjects_affected="168" subjects_at_risk="220"/>
                <counts group_id="E2" events="488" subjects_affected="157" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="220"/>
                <counts group_id="E2" events="47" subjects_affected="36" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="220"/>
                <counts group_id="E2" events="33" subjects_affected="29" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>General complaint, unspecified</sub_title>
                <counts group_id="E1" events="791" subjects_affected="190" subjects_at_risk="220"/>
                <counts group_id="E2" events="810" subjects_affected="187" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>General complaint, unspecified</sub_title>
                <counts group_id="E1" events="217" subjects_affected="115" subjects_at_risk="220"/>
                <counts group_id="E2" events="252" subjects_affected="123" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="211" subjects_affected="107" subjects_at_risk="220"/>
                <counts group_id="E2" events="204" subjects_affected="105" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>fungal skin infection</sub_title>
                <counts group_id="E1" events="102" subjects_affected="64" subjects_at_risk="220"/>
                <counts group_id="E2" events="70" subjects_affected="46" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>angular chelitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="220"/>
                <counts group_id="E2" events="45" subjects_affected="34" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="220"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="220"/>
                <counts group_id="E2" events="40" subjects_affected="32" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1242" subjects_affected="212" subjects_at_risk="220"/>
                <counts group_id="E2" events="1226" subjects_affected="212" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E2" events="40" subjects_affected="23" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Intestinal helminthiasis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="220"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="55" subjects_affected="41" subjects_at_risk="220"/>
                <counts group_id="E2" events="55" subjects_affected="33" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gonorrhea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="220"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Genito-urinary disease (GUD)</sub_title>
                <counts group_id="E1" events="52" subjects_affected="39" subjects_at_risk="220"/>
                <counts group_id="E2" events="131" subjects_affected="77" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Vaginal candidiasis</sub_title>
                <counts group_id="E1" events="134" subjects_affected="80" subjects_at_risk="220"/>
                <counts group_id="E2" events="159" subjects_affected="79" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="48" subjects_affected="36" subjects_at_risk="220"/>
                <counts group_id="E2" events="55" subjects_affected="39" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic injury</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="220"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="220"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Musculoskeletal joint pain, unspecified</sub_title>
                <counts group_id="E1" events="470" subjects_affected="165" subjects_at_risk="220"/>
                <counts group_id="E2" events="472" subjects_affected="162" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HIV neuritis</sub_title>
                <counts group_id="E1" events="45" subjects_affected="36" subjects_at_risk="220"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>post-herpetic neuralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Nervous system, other complaint</sub_title>
                <counts group_id="E1" events="76" subjects_affected="55" subjects_at_risk="220"/>
                <counts group_id="E2" events="68" subjects_affected="46" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="220"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="220"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Genitourinary, other complaint</sub_title>
                <counts group_id="E1" events="280" subjects_affected="131" subjects_at_risk="220"/>
                <counts group_id="E2" events="356" subjects_affected="140" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory complaint, unspecified</sub_title>
                <counts group_id="E1" events="152" subjects_affected="98" subjects_at_risk="220"/>
                <counts group_id="E2" events="132" subjects_affected="82" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Papulo-pruritic eruption (PPE)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Darkening nails</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="220"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Rash, unspecified</sub_title>
                <counts group_id="E1" events="227" subjects_affected="118" subjects_at_risk="220"/>
                <counts group_id="E2" events="201" subjects_affected="119" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Skin complaint, unspecified</sub_title>
                <counts group_id="E1" events="213" subjects_affected="123" subjects_at_risk="220"/>
                <counts group_id="E2" events="212" subjects_affected="122" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Reynolds</name_or_title>
      <organization>NIAID</organization>
      <phone>256-772-220-087</phone>
      <email>sjreynolds@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

